Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typical treatments for this…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…
ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-…
Parkinson’s disease (PD) treatment is complex. The disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine…
According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency,…
Market Outlook Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
MARKET OUTLOOKThe accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
For the estimated 5 million people in the United States with atrial fibrillation (AF), several treatment approaches can be used, each of which has a wide range of pharmacological options…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…
